Johnson & Johnson Company Profile (NYSE:JNJ)

About Johnson & Johnson

Johnson & Johnson logoJohnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company's segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women's health and wound care markets. The Pharmaceutical segment is focused on over five therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment includes a range of products used in the orthopedic, surgery, cardiovascular, diabetes care and vision care fields. Its research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: Pharmaceuticals
  • Exchange: NYSE
  • Symbol: JNJ
  • CUSIP: 47816010
Key Metrics:
  • Previous Close: $119.47
  • 50 Day Moving Average: $122.75
  • 200 Day Moving Average: $114.75
  • 52-Week Range: $89.90 - $126.07
  • Trailing P/E Ratio: 22.21
  • Foreward P/E Ratio: 16.78
  • P/E Growth: 2.74
  • Market Cap: $326.03B
  • Outstanding Shares: 2,735,876,000
  • Beta: 0.56
Additional Links:
Companies Related to Johnson & Johnson:

Analyst Ratings

Consensus Ratings for Johnson & Johnson (NYSE:JNJ) (?)
Ratings Breakdown: 1 Sell Rating, 11 Hold Ratings, 10 Buy Ratings
Consensus Rating:Hold (Score: 2.41)
Consensus Price Target: $118.38 (0.80% downside)

Analysts' Ratings History for Johnson & Johnson (NYSE:JNJ)
DateFirmActionRatingPrice TargetDetails
8/25/2016BTIG ResearchReiterated RatingNeutralView Rating Details
8/19/2016Deutsche Bank AGReiterated RatingBuy$142.00View Rating Details
8/4/2016Jefferies GroupBoost Price TargetHold$113.00 -> $119.00View Rating Details
7/20/2016RBC Capital MarketsReiterated RatingOutperform$125.00 -> $133.00View Rating Details
7/20/2016Leerink SwannReiterated RatingOutperform$125.00 -> $140.00View Rating Details
7/20/2016BMO Capital MarketsReiterated RatingOutperform$132.00View Rating Details
7/20/2016Royal Bank Of CanadaBoost Price TargetOutperform$125.00 -> $133.00View Rating Details
7/11/2016Wells Fargo & Co.Reiterated RatingBuyView Rating Details
7/10/2016Barclays PLCReiterated RatingOverweight$120.00 -> $125.00View Rating Details
6/13/2016Goldman Sachs Group Inc.Set Price TargetNeutral$121.00View Rating Details
5/20/2016Raymond James Financial Inc.Reiterated RatingOutperform$120.00View Rating Details
5/20/2016Standpoint ResearchInitiated CoverageSell$94.00View Rating Details
5/19/2016Bank of America Corp.Reiterated RatingHoldView Rating Details
5/19/2016Morgan StanleyReiterated RatingHoldView Rating Details
5/19/2016Credit Suisse Group AGReiterated RatingHold$112.00View Rating Details
4/20/2016Piper Jaffray Cos.Boost Price TargetNeutral$105.00 -> $106.00View Rating Details
4/20/2016ArgusBoost Price TargetBuy$116.00 -> $130.00View Rating Details
4/17/2016JPMorgan Chase & Co.Reiterated RatingHoldView Rating Details
4/6/2016Societe GeneraleInitiated CoverageHold$113.00View Rating Details
1/27/2016Independent Research GmbHSet Price TargetNeutral$108.00View Rating Details
12/18/2015Atlantic SecuritiesInitiated CoverageNeutral$95.00View Rating Details
10/15/2015S&P Equity ResearchReiterated RatingBuy$120.00View Rating Details
8/25/2015Cowen and CompanyReiterated RatingOutperform$114.00View Rating Details
10/2/2014GuggenheimInitiated CoverageNeutral$115.00View Rating Details
10/1/2014Sanford C. BernsteinDowngradeOutperform -> Market PerformView Rating Details
(Data available from 8/31/2014 forward)


Earnings History for Johnson & Johnson (NYSE:JNJ)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/19/2016Q216$1.68$1.74$17.98 billion$18.50 billionViewListenView Earnings Details
4/19/2016Q116$1.65$1.68$17.50 billion$17.50 billionViewListenView Earnings Details
1/26/2016Q415$1.42$1.44$17.88 billion$17.80 billionViewListenView Earnings Details
10/13/2015Q315$1.45$1.49$17.47 billion$17.10 billionViewListenView Earnings Details
7/14/2015Q215$1.69$1.71$17.76 billion$17.80 billionViewListenView Earnings Details
4/14/2015Q115$1.54$1.56$17.40 billionViewListenView Earnings Details
1/20/2015Q414$1.26$1.27$18.59 billion$18.30 billionViewListenView Earnings Details
10/14/2014Q314$1.43$1.50$18.41 billion$18.50 billionViewListenView Earnings Details
7/15/2014Q214$1.54$1.66$18.86 billion$19.50 billionViewN/AView Earnings Details
4/15/2014Q114$1.48$1.54$18.00 billion$18.10 billionViewN/AView Earnings Details
1/21/2014Q413$1.20$1.24$17.95 billion$18.40 billionViewN/AView Earnings Details
10/15/2013Q313$1.32$1.36$17.46 billion$17.60 billionViewN/AView Earnings Details
7/16/2013Q2 2013$1.39$1.48$17.71 billion$17.90 billionViewN/AView Earnings Details
4/16/2013Q1 2013$1.41$1.44$17.46 billion$17.50 billionViewN/AView Earnings Details
1/22/2013Q4 2012$1.17$1.19$17.67 billion$17.60 billionViewN/AView Earnings Details
10/16/2012$1.21$1.25ViewN/AView Earnings Details
7/17/2012$1.29$1.30ViewN/AView Earnings Details
4/17/2012$1.34$1.37ViewN/AView Earnings Details
1/24/2012$1.09$1.13ViewN/AView Earnings Details
10/18/2011$1.21$1.24ViewN/AView Earnings Details
7/19/2011$1.24$1.28ViewN/AView Earnings Details
4/19/2011$1.26$1.35ViewN/AView Earnings Details
1/25/2011$1.03$1.03ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Johnson & Johnson (NYSE:JNJ)
Current Year EPS Consensus Estimate: $6.69 EPS
Next Year EPS Consensus Estimate: $7.11 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162$1.60$1.67$1.64
Q2 20163$1.64$1.68$1.66
Q3 20161$1.63$1.63$1.63
Q4 20161$1.59$1.59$1.59
Q1 20172$1.69$1.73$1.71
Q2 20171$1.82$1.82$1.82
Q3 20171$1.82$1.82$1.82
Q4 20171$1.79$1.79$1.79
Q1 20181$1.91$1.91$1.91
Q2 20181$2.00$2.00$2.00
(Data provided by Zacks Investment Research)


Current Dividend Information for Johnson & Johnson (NYSE:JNJ)
Annual Dividend:$3.20
Dividend Yield:2.68%
Dividend Growth:7.10% (3 Year Average)
Payout Ratio:60.15% (Based on Trailing 12 Months of Earnings)
47.83% (Based on Current Year Consensus EPS Estimate)
45.01% (Based on Next Year Consensus EPS Estimate)
Track Record:53 Years of Consecutive Dividend Growth

Dividend History for Johnson & Johnson (NYSE:JNJ)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Johnson & Johnson (NYSE:JNJ)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/26/2016Dominic J CarusoVPSell41,146$125.01$5,143,661.46View SEC Filing  
7/22/2016Ronald A KapustaCAOSell2,935$125.01$366,904.35View SEC Filing  
6/7/2016Gary J PrudenVPSell9,735$116.03$1,129,552.05View SEC Filing  
6/7/2016Ronald A KapustaCAOSell3,000$115.79$347,370.00View SEC Filing  
5/10/2016Ronald A KapustaCAOSell3,957$114.77$454,144.89View SEC Filing  
2/17/2016Paulus StoffelsinsiderSell125,000$102.43$12,803,750.00View SEC Filing  
2/3/2016Peter FasoloVPSell151,385$104.12$15,762,206.20View SEC Filing  
10/23/2015Ronald A. KapustaCAOSell6,239$99.68$621,903.52View SEC Filing  
6/2/2015Charles PrinceDirectorBuy2,500$99.22$248,050.00View SEC Filing  
4/28/2015Paulus StoffelsInsiderSell187,250$100.73$18,861,692.50View SEC Filing  
9/10/2014James CullenDirectorSell2,446$104.12$254,677.52View SEC Filing  
5/5/2014Stephen CosgroveInsiderSell22,000$100.05$2,201,100.00View SEC Filing  
3/14/2014Peter FasoloVPSell6,824$93.15$635,655.60View SEC Filing  
8/14/2013Stephen CosgroveInsiderSell17,200$91.39$1,571,908.00View SEC Filing  
8/5/2013Michael UllmannVPSell16,140$93.68$1,511,995.20View SEC Filing  
7/25/2013Paulus StoffelsInsiderSell45,440$92.40$4,198,656.00View SEC Filing  
7/18/2013Dominic J CarusoCFOSell30,000$90.31$2,709,300.00View SEC Filing  
11/12/2012James CullenDirectorSell13,900$69.70$968,830.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Johnson & Johnson (NYSE:JNJ)
DateHeadline logoHow Johnson & Johnson's Partnerships Enhance Customer Value - Market Realist (NYSE:JNJ) - August 31 at 10:34 AM logoJohnson & Johnson to Participate in 2016 Morgan Stanley Global Health Care Conference (NYSE:JNJ) - August 31 at 10:34 AM logoLatest Analyst Recommendations for Johnson & Johnson (NYSE:JNJ) - August 31 at 10:34 AM logoTop 10 Dividend Stocks to Buy in September (NYSE:JNJ) - August 31 at 10:34 AM
News IconWorth Watching Stocks Roundup: Johnson & Johnson (NYSE:JNJ), Visa Inc(NYSE:V), Tesla Motors Inc (NASDAQ:TSLA) - NYSE Journal (press release) (NYSE:JNJ) - August 30 at 5:48 PM logoThere's More to Johnson & Johnson (JNJ) Than Meets the Eye - (NYSE:JNJ) - August 30 at 5:48 PM logoWhat’s Johnson & Johnson’s Pharmaceuticals Segment? (NYSE:JNJ) - August 30 at 5:48 PM logoJohnson & Johnson’s Latest Dividend Payment: Is It Important? (NYSE:JNJ) - August 30 at 5:48 PM logoThese 3 Billionaires Dumped Johnson & Johnson Stock. Should You? (NYSE:JNJ) - August 30 at 9:01 AM logoJohnson & Johnson Vs. The S&P 500 (NYSE:JNJ) - August 29 at 5:39 PM
News IconBank of America Corp (NYSE:BAC) & Johnson & Johnson (NYSE:JNJ) UPDATE ON U.S STOCKS : 26 AUG 2016 - Money News (press release) (NYSE:JNJ) - August 29 at 10:17 AM logoJohnson & Johnson Vs. The S&P 500 - Seeking Alpha (NYSE:JNJ) - August 29 at 10:17 AM logoProof that you can't afford to ignore the power of dividends (NYSE:JNJ) - August 28 at 10:00 AM
News IconJohnson & Johnson's (JNJ): Eye-Catching Stock - Hot Stocks Point (NYSE:JNJ) - August 26 at 8:46 AM logoJohnson & Johnson (NYSE:JNJ) Janssen Biotech Inc. Files sBLA For DARZALEX (NYSE:JNJ) - August 25 at 5:48 PM
News IconJohnson & Johnson's (JNJ): Monitor the Current Moves - Hot Stocks Point (NYSE:JNJ) - August 25 at 10:49 AM
News IconJohnson & Johnson (JNJ): This Dividend Aristocrat is a Perfect Stock ... - Economic Calendar (NYSE:JNJ) - August 25 at 10:49 AM logoJohnson & Johnson to Participate in the 2016 Wells Fargo 11th Annual Healthcare Conference (NYSE:JNJ) - August 25 at 10:49 AM logoJanssen Submits Application to the European Medicines Agency (EMA) to Expand Use of DARZALEX®▼ (daratumumab) to Include Combination with Standard of Care Regimens (NYSE:JNJ) - August 25 at 10:49 AM
News IconEthicon, Touch Surgical debut surgeon training app (NYSE:JNJ) - August 24 at 5:40 PM logoJohnson & Johnson (NYSE:JNJ) Remicade's Outlook Lowered by BTIG, Reiterated as Neutral (NYSE:JNJ) - August 24 at 5:40 PM logoHow MAKO Robots Could Contribute to SYK’s Orthopedics Growth (NYSE:JNJ) - August 24 at 5:40 PM logoMerck Offers Value and Steady Dividend Growth (NYSE:JNJ) - August 24 at 5:40 PM
News IconJohnson & Johnson (JNJ): This Dividend Aristocrat is a Perfect Stock for Retirees’ Portfolio (NYSE:JNJ) - August 24 at 8:51 AM logoJohnson & Johnson: Don't Let High P/Es Panic You Into Selling (NYSE:JNJ) - August 24 at 8:51 AM logo[$$] MPs call for ban on microbeads in toiletries (NYSE:JNJ) - August 24 at 8:51 AM logoJohnson & Johnson Could Become the First Company to Reach a ... - Motley Fool (NYSE:JNJ) - August 23 at 5:57 PM logoApril 2017 Options Now Available For Johnson & Johnson (JNJ) - Forbes (NYSE:JNJ) - August 23 at 5:57 PM logo7:00 am Johnson & Johnson and Genmab (GMXAY (NYSE:JNJ) - August 23 at 10:09 AM logoWill Johnson & Johnson (JNJ) Survive after Remicade Patent Loss? (NYSE:JNJ) - August 22 at 5:48 PM logoApril 2017 Options Now Available For Johnson & Johnson (JNJ) (NYSE:JNJ) - August 22 at 5:48 PM logoS&P 500, Dow industrials book a loss as oil snaps win streak (NYSE:JNJ) - August 22 at 5:48 PM
News IconTrend Analysis Report: NetApp Inc. (NASDAQ:NTAP), Johnson & Johnson (NYSE:JNJ) - NYSE Journal (press release) (NYSE:JNJ) - August 22 at 10:21 AM logoWill Johnson & Johnson (JNJ) Survive after Remicade Patent Loss? - TCC (NYSE:JNJ) - August 22 at 10:21 AM logoJohnson & Johnson Could Become the First Company to Reach a $1 Trillion Valuation (NYSE:JNJ) - August 22 at 8:47 AM logoJohnson & Johnson: Grim Future Dividend Outlook Means Shares Are Overvalued Right Now (NYSE:JNJ) - August 21 at 5:16 PM
News IconInsider Activity to Watch: Johnson & Johnson (JNJ) - The Voice Registrar (NYSE:JNJ) - August 20 at 5:36 PM
News IconJohnson & Johnson (JNJ) – No More Tears (NYSE:JNJ) - August 19 at 5:46 PM
News IconJohnson & Johnson Is a Good Bet (NYSE:JNJ) - August 19 at 5:46 PM logoHow Does Bristol-Myers Squibb’s Valuation Compare to Peers? (NYSE:JNJ) - August 19 at 5:46 PM logoBRIEF-Johnson & Johnson reports 15 pct passive stake in Protagonist Therapeutics - SEC filing (NYSE:JNJ) - August 19 at 11:43 AM logoPursche: A disconnect between fundamentals and valuations (NYSE:JNJ) - August 18 at 5:48 PM logoDeutsche Takes A Look At Johnson & Johnson's Patent Woes (NYSE:JNJ) - August 18 at 4:18 PM logoWhy I Hate Johnson & Johnson Right Now (But I'll Never Sell) (NYSE:JNJ) - August 18 at 11:41 AM
News IconJohnson & Johnson's (JNJ): Active Stock of Yesterday - Hot Stocks Point (NYSE:JNJ) - August 18 at 8:50 AM
News IconHC Stocks in Hub: Johnson & Johnson (NYSE:JNJ), StemCells Inc (NASDAQ:STEM) - share market updates (press release) (NYSE:JNJ) - August 18 at 8:50 AM logoGreater Cincinnati firm faces lawsuit over deceptive marketing allegations (NYSE:JNJ) - August 18 at 8:50 AM logoJ&J (JNJ) Remicade Patent Invalid, Pfizer to Launch Inflectra? (NYSE:JNJ) - August 18 at 8:50 AM logoCourt rules Remicade patent is invalid (NYSE:JNJ) - August 18 at 8:50 AM logoJohnson & Johnson (JNJ) Receives Adverse Ruling in REMICADE Patent Litigation - (NYSE:JNJ) - August 17 at 5:59 PM


Johnson & Johnson (NYSE:JNJ) Chart for Wednesday, August, 31, 2016

Last Updated on 8/31/2016 by Staff